OpGen, Inc.

OPGN

US68373L5057

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 03:22:15 2025-07-09 pm EDT			5-day change	1st Jan Change
4.600 ^USD	-6.69%		-3.36%	+673.11%

2024	OpGen, Inc. Appoints Management Team	CI
2024	OpGen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI

Top Premarket Gainers

Published on 09/29/2023 at 07:46, updated on 09/29/2023 at 07:47

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about OpGen, Inc.

OpGen, Inc. Appoints Management Team	Dec. 06	CI
OpGen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Nov. 15	CI
OpGen, Inc. announced that it expects to receive $3 million in funding	24-08-21	CI
OpGen, Inc.(OTCPK:OPGN) dropped from S&P TMI Index	24-08-21	CI
OpGen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	24-08-19	CI
OpGen, Inc.(OTCPK:OPGN) dropped from NASDAQ Composite Index	24-08-18	CI
OpGen, Inc. Announces Board and Committee Appointments	24-08-15	CI
Opgen, Inc. Announces Board Changes	24-08-02	CI
OpGen, Inc. Announces Chief Executive Officer Changes	24-08-02	CI
OpGen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	24-07-08	CI
OpGen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	24-06-03	CI
OpGen, Inc. Auditor Raises 'Going Concern' Doubt	24-06-02	CI
OpGen, Inc. Announces Appointments to the Committees of the Board	24-05-30	CI
OpGen Gets Notice of Noncompliance From Nasdaq	24-04-24	MT
Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading	24-03-26	MT
OpGen, Inc. Announces Management Changes	24-03-25	CI
OpGen, Inc. Announces Chief Executive Officer Changes	24-03-25	CI
OpGen, Inc. announced that it has received $0.2 million in funding	24-03-24	CI
Earnings Flash (OPGN) OPGEN Posts Q3 Revenue $699,022	23-11-14	MT
OpGen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-11-14	CI
OpGen to Raise $1 Million From Private Placement Amid Talks For 'Potential Strategic' Deal	23-10-12	MT
OpGen, Inc. announced that it expects to receive $1 million in funding	23-10-10	CI
Wall Street Set to Open Higher; Personal Consumption Inflation Data Lower Than Expected	23-09-29	MT
Investors Await Inflation Data, Consumer Sentiment Report as US Futures Trend Higher Friday	23-09-29	MT
Top Premarket Gainers	23-09-29	MT

OpGen, Inc. is a precision medicine company that uses molecular diagnostics and informatics to combat infectious diseases. The Company distributes molecular microbiology solutions that help guide clinicians with more information about life threatening infections to improve patient outcomes and decrease the spread of infections caused by multidrug-resistant microorganisms (MDROs). The Company's product portfolio includes Unyvero Lower Respiratory Tract Panels, Unyvero Urinary Tract Infection Panel, Unyvero System, and Unyvero Resources. The Unyvero LRT panels enable comprehensive detection of the most clinically relevant pathogens and antibiotic resistance markers. The Unyvero Urinary Tract Infection (UTI) panel simultaneously identifies a comprehensive range of pathogens and antibiotic resistance markers associated with urinary tract infections. The Unyvero system uses multiplex PCR technology to simultaneously test for a range of microorganisms and antibiotic resistance markers.

Employees

Sector

Biotechnology & Medical Research

More about the company